examined serum AGE levels in various patient groups including peritoneal dialysis and hemodialysis patients, using an immunological procedure that we developed. Three independent reports have recently confirmed that it is possible to raise antibodies reacting with diverse AGEs, including those produced by reacting glucose with amino acids [7] [8] [9] . These reports speculate that all AGEs share a common haptenic antigenic determinant which is very useful for monitoring AGE levels in tissues and serum.
Methods

Reagents
Bovine pancreatic ribonuclease (RNase), bovine serum albumin (BSA) and all sugars used were from Sigma Chemical Co. (St. Louis, Missouri, USA). AGE-RNase (the immunogen) was prepared by mixing 10 ml of phosphate buffer (0.2 mollliter, pH 7.40, containing 0.5 mmol EDTA) 250 mg RNase and 1.80 g glucose, dissolving and filtering through a 0.2 m filter and incubating for three months at 37°C (air-oven) [9] . One preparation without glucose was incubated under the same conditions as a control. The same procedure was also used to prepare an AGE-BSA solution which was used as a coating antigen in the assay, as described below. The stock AGE-BSA solution contained 50mg of BSA/mI. Mter incubation, the unbound material was removed by extensive dialysis against phosphate-buffered saline.
Immunization While female New Zealand rabbits were immunized with the AGE-RNase immunogen, which was emulsified with an equal volume of complete Fruend's adjuvant (Sigma). About 50 d of immunogen were injected subcutaneously every two to three weeks at two different sites. Just prior to each injection, blood was drawn for antibody testing. A total of eight injections were given, and all booster injections were performed with the immunogen in incomplete adjuvant. High titers of antibodies developed after 10 to 12 weeks. The development of the AGE antibodies was monitored with a solid-phase assay described under "Procedures." The rabbit antiserum was used without further purification.
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Tb-EDTA Fluorescent product FSA-Tb-EDTA complex Bo. The fluorescence of all other standards was defined as B. In the same plot we present the (BIB0) x 100 values of a serum sample that was analyzed undiluted or diluted 2-, 4-or 8-fold (•).
Instrumentation
For measuring liquid-phase Tb3 fluorescence in white microtiter wells, the CyberFluor 615TM Immunoanalyzer, a timeresolved fluorometer, was used as previously described [10, 111. These standards were prepared from a stock AGE-BSA solution with total protein of 50 mg/mI, equivalent to 50,000 U/ml. As also defined by others [9] , one AGE unit is equivalent to 1 sg of AGE-BSA.
Patient samples and statistical analysis Sera from various groups of patients were stored at -70°C until analysis (up to 2 months). All comparisons were determined by paired or unpaired Student's t-test as appropriate. All P values of less than 0.05 were considered to indicate statistical significance.
Immunoassay procedure
White, opaque 12-well microtiter strips (from Dynatech Labs, Alexandria, Virginia, USA) were coated with the AGE-BSA complex diluted in the coating buffer (100 dI2.5 zgIwell; overnight incubation at room temperature). Before the assay, the wells were washed six times with the wash solution, using an automated washing device. In each well 100 p1 of each standard or serum sample (all in triplicate) were added to 50 d of the rabbit anti-AGE antiserum diluted 2,000-fold in the assay buffer, incubated with shaking for two hours at room temperature and washed six times. One hundred p1/well of the alkaline phosphatase-labeled goat anti-rabbit immunoglobulin was added, diluted 5,000-fold in the assay buffer, incubated for one hour as above and washed six times. One hundred p1/well of the alkaline phosphatase substrate FSAP, diluted to iO mol/liter in the enzyme substrate buffer was added, and incubated for 10 minutes at room temperature with shaking. Then, 100 p1/well of the developing solution was added, mixed for one minute, and the Th3-specific fluorescence measured in the time-resolved mode as previously described [10, 11] . Data reduction was automatic through the CyberFluor 615TM Immunoanalyzer.
To monitor antibody titers during immunization, a similar assay procedure was used. The differences are as follows: (a) only the zero standard was used, and (b) the antiserum was used at various dilutions. The antibody titer was defined as the antiserum dilution that gave 50% of the maximum fluorescence count. For the assay, the antiserum titer was about 2,000. found to be 360 and 445 nm, respectively, which is in close agreement with previously published data [12] .
The immunological procedure that we developed was similar to the one described by Makita et al [9] , but for detection, we used a methodology based on enzymatically amplified time resolved fluorometry with terbium chelates, as previously described [10, 11] . In our assay (Fig. 1) immobilized AGE (AGE-BSA) competed with the AGE in the serum sample or standards, for binding to a limited amount of anti-AGE rabbit antibodies. The degree of binding of the antibody to the solid-phase was inversely related to the amount of AGE in the sample. Antibody binding was quantified with a goat anti-rabbit antibody covalently linked to alkaline phosphatase (ALP). The ALP substrate used was FSAP, which was converted to 5-fluorosalicylate (FSA). FSA is able to form a ternary fluorescent complex with Th-EDTA of a long fluorescence lifetime [13] .
A typical calibration curve for the AGE assay is shown in Figure 2 . This assay measured AGE up to 110 U/mi and had a detection limit of approximately 1 U/mi. The precision of the assay at various AGE concentrations is shown in Table 1 .
Recovery experiments done by spiking patient sera with AGE-BSA are summarized in Table 2 . The possible interference of simple sugars, that is, glucose, xylitol, dulcitol and galactose, was tested at concentrations as high as 60 mmol/liter and of heparin at contentrations up to 1000 U/mI. None interfered to any measurable degree. Three samples with high AGE concentration were analyzed undiluted or diluted two-, four-or eightfold using a 6% BSA solution as diluent. The results are shown in Figure 3 . The near-linear relationship between AGE concentration and dilution further suggested that the AGEs in serum and AGE-BSA share a common antigenic determinant [7] [8] [9] . A serum sample was plotted, diluted either two-, four-or eightfold along with the standard curve (Fig. 2) . For this experiment, the AGE concentration in the undiluted sample was calculated from the standard curve and the fluorescence of the dilutions plotted, expressed as (B/Bo) x 100, versus the concentration of AGE as predicted by the dilution factor. The two curves, obtained with AGE-BSA and diluted serum, are closely related (Fig. 2) .
The results of AGE analysis in various groups of patients are summarized in Table 3 . The mean values of AGEs in normal subjects and diabetics with normal renal function were statistically different (P < 0.001). Patients with renal failure without diabetes and patients treated with continuous ambulatory pentoneal dialysis (CAPD) or hemodialysis had highly elevated serum levels of AGE, irrespective of their glycemic status.
Comparison of various groups of patients with respect to AGE concentration, by the Student's 1-test, revealed highly significant differences between the following groups: normals versus diabetics; normals versus NIDDM; normals versus IDDM; normals versus CAPD (all patients); normals versus hemodialysis (all patients); diabetics versus CAPD (all patients); and diabetics versus hemodialysis (all patients). In all cases the P values were <0.004. In contrast, comparison of the following groups with respect to AGE concentration gave no statistically significant differences: CAPD versus hemodialysis (P = 0.13); renal failure patients (non-treated) versus CAPD (P = 0.56); renal failure patients (non-treated) versus hemodialysis (P = 0.72); CAPD, non-diabetics versus CAPD, NIDDM (P = 0.59); CAPD, non-diabetics versus CAPD, IDDM (P = 0.62).
The results of whether AGE concentration was associated with serum glucose or creatinine levels, sex or age are summarized in Figure 4 . No correlation or association existed between AGE levels and glucose, sex or age. However, there was a strong correlation between AGE levels and creatinine in both the CAPD and hemodialysis patient groups. The variation of AGE levels during hemodialysis was also examined. For these studies, predialysis and postdialysis AGE and creatinine levels were compared in three groups of patients: non-diabetics, NIDDM and IDDM (Fig. 5) . In all cases there was a highly significant drop in AGE levels after hemodialysis, which suggests that the AGEs are relatively effectively cleared.
Nine patients were studied to determine if the AGE accumulation in renal failure patients was the result of the hemodialysis or CAPD treatment or if it occurred before the treatment was initiated (Table 3) . These patients had renal failure but blood sampling for AGE analysis was obtained before the initiation of therapy. The AGE levels were elevated in these patients, confirming that the AGE accumulation was not a consequence of the treatment.
Molecular weight identification of AGE
One ml of a patient serum sample with high AGE concentration was dialyzed against 5 liters of saline overnight using a dialysis membrane with a cutoff level of 12,000 Da. Analysis of the AGE levels in the serum, after dialysis, showed an 80% decrease, suggesting that AGE was effectively dialyzed. Similar results were obtained when the sample was ultrafiltered using Amicon filters and centrifugation. To further identify the molecular weight of AGE, one serum sample was chromatographed through a Bio-Sil SEC-250 column, 600 mm x 7.5 mm (Bio-Rad Laboratories, Richmond, California, USA) using a mobile phase of 0.1 mol/liter Na2SO4-0. 1 moL/liter NaH2PO4, pH 6.80, at a flow rate of 0.5 mllmin. After injecting 1 ml sample, 0.5 ml fractions were collected and analyzed for AGEs.
The column was calibrated with a molecular weight standard solution from BioRad. The results are shown in Figure 6 . Clearly, AGEs elute at a peak corresponding to a molecular weight of 1500 to 2000 daltons.
Discussion
Advanced glycosylation end-products are candidate pathogenetic factors of the long-term complications of diabetes. Extensive clinical studies on AGEs, especially with assessment of the serum levels, are lacking partially because their measurement is difficult and commercial assays are not available. This paper describes an immunological assay for AGEs in serum, based on a rabbit antibody that was raised with AGE-RNase as immunogen, as described by Makita et al [9] . AGE formation was followed by fluorometric procedures. Our competitive assay utilizes a solid-phase AGE-BSA complex and a detection methodology based on time-resolved fluorometry with terbium chelates as labels [10] [11] [12] . The assay was found to be precise, accurate and easy to perform. No interference by simple sugars or heparin was observed, in accordance with reports by three other groups [7] [8] [9] which suggest that anti-AGE antibodies, raised following the procedures described, react with an epitope specific and common to all AGEs. This epitope is not present in early glycosylated products or synthetic model AGE molecules hemodialysis. No association was found between AGE levels and sex, age or serum glucose levels. Other studies have shown that AGEs pre-exist in patients with renal failure and are not the consequence of the therapy.
The molecular weight of the circulating AGEs is around 1500
to 2000 Da as found by high performance liquid chromatographic studies. Currently, it is believed that serum AGEs are peptides in nature but this has not yet been confirmed, nor is their precise structure known. We are currently examining if the measurement of AGEs in serum by the immunological assay described has clinical significance in predicting the long-term complications of diabetic and non-diabetic nephropathy. 
